on this page
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with azacitidine (injection), daunorubicin+cytarabine and midostaurin under the National Health Act 1953, section 100 for patients with AML.
The PBS subsidises treatment with azacitidine (tablet) and decitabine+cedazuridine under the National Health Act, section 85 for patients with AML.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin.
Section 100 arrangements - Highly Specialised Drugs
azacitidine (injection) and midostaurin
These items are only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending either:
- an approved private hospital
- a public hospital.
These items aren’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.
Section 100 - Efficient Funding of Chemotherapy
daunorubicin+cytarabine
This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending either:
- an approved private hospital
- a public participating hospital.
This item isn’t PBS-subsidised for hospital in-patients.
Authority applications
azacitidine (injection)
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised azacitidine injection to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Continuing PBS-subsidised treatment with azacitidine injection is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
azacitidine (tablet)
Applying for initial treatment following intensive induction chemotherapy
Applications for initial authority approval to prescribe PBS-subsidised azacitidine (tablet) to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment following intensive induction chemotherapy
Applications for continuing authority approval to prescribe PBS-subsidised azacitidine (tablet) to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment - dose escalation therapy
Applications for continuing authority approval to prescribe PBS-subsidised azacitidine (tablet) as dose escalation therapy to treat AML can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed acute myeloid leukaemia - oral azacitidine - dose escalation therapy continuing authority application form
- relevant attachments.
decitabine+cedazuridine
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals enquiry line.
Applying for continuing treatment
Continuing PBS-subsidised treatment with decitabine+cedazuridine is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
daunorubicin+cytarabine
Applying for induction treatment
Applications for induction authority approval to prescribe PBS-subsidised daunorubicin+cytarabine to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for consolidation treatment
Applications for consolidation authority approval to prescribe PBS-subsidised daunorubicin+cytarabine to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
midostaurin
Applying for induction and consolidation treatment
Applications for induction and consolidation authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for initial maintenance treatment
Applications for initial maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed acute myeloid leukaemia - midostaurin - initial maintenance authority application form
- relevant attachments.
Applying for continuing maintenance treatment
Applications for continuing maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.